Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributor.authorBamias, A.en
dc.contributor.authorPapamichael, D.en
dc.contributor.authorSyrigos, K.en
dc.contributor.authorPavlidis, N.en
dc.rightsDefault Licence-
dc.subjectAdenocarcinoma/*drug therapy/mortality/pathologyen
dc.subjectAntineoplastic Combined Chemotherapy Protocols/*administration & dosage/*adverseen
dc.subjectCamptothecin/administration & dosage/adverse effects/*analogs & derivativesen
dc.subjectChi-Square Distributionen
dc.subjectColorectal Neoplasms/*drug therapy/mortality/pathologyen
dc.subjectDose-Response Relationship, Drugen
dc.subjectDrug Administration Scheduleen
dc.subjectDrug Toxicityen
dc.subjectFluorouracil/administration & dosage/adverse effectsen
dc.subjectFollow-Up Studiesen
dc.subjectMaximum Tolerated Doseen
dc.subjectMiddle Ageden
dc.subjectMitomycin/administration & dosage/adverse effectsen
dc.subjectNeoplasm Stagingen
dc.subjectOdds Ratioen
dc.subjectRisk Assessmenten
dc.subject*Salvage Therapyen
dc.subjectStomach Neoplasms/*drug therapy/mortality/pathologyen
dc.subjectSurvival Analysisen
dc.titlePhase II study of irinotecan and mitomycin C in 5-fluorouracil-pretreated patients with advanced colorectal and gastric canceren
heal.type.enJournal articleen
heal.type.elΆρθρο Περιοδικούel
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.abstractThe aim of this phase II study was to investigate the tolerance and efficacy of a second-line irinotecan/mitomycin C combination in patients with advanced gastric or colorectal cancer, pretreated with 5-fluorouracil. Forty patients who had received 5-fluorouracil-based chemotherapy for advanced disease or adjuvant 5-fluorouracil treatment were enrolled. Chemotherapy consisted of irinotecan 125 mg/m2 and mitomycin C 5 mg/m2, given every 2 weeks. Treatment was continued until progression or limiting toxicity occurred. Five partial responses (12.5%), 22 cases of stable disease (55%) and 13 of progression (32.5%) were registered, giving an overall response rate of 12.5% [95% confidence interval (CI), 4.2-26.8%] and an overall control of tumor growth in 67.5% (95% CI, 50.8-81.4%) of patients. Median progression-free survival was 5 months, median survival time 8 months, and 1-year probability of survival was 21.6%. Diarrhea and neutropenia affected 25% and 12.5% of patients respectively, with only 7.5% experiencing grade 3-4 toxicity. There were no chemotherapy-related deaths or hospitalizations. This combination regimen was shown to be moderately effective with substantially lower toxicity than irinotecan monotherapy in 5-fluorouracil-pretreated patients with advanced gastric or colorectal cancer. It may represent an attractive option in patients at high risk for developing specific irinotecan toxicity.en
heal.journalNameJ Chemotheren
Appears in Collections:Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά)

Files in This Item:
There are no files associated with this item.

This item is licensed under a Creative Commons License Creative Commons